Prevention of Bronchiectasis in Infants With Cystic Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2021

Conditions
Cystic FibrosisBronchiectasis
Interventions
DRUG

Azithromycin

azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age

DRUG

Placebo control

inert liquid preparation will be given three times per week from three months of age to three years of age

Trial Locations (10)

4101

Queensland Children's Hospital, Brisbane

6009

Perth Children's Hospital, Perth

Unknown

Sydney Children's Hospital, Sydney

Westmead Children's Hospital, Sydney

Mater Children's Hospital, Brisbane

Royal Children's Hospital, Brisbane

Women's and Children's Hospital, Adelaide

Monash Medical Centre, Melbourne

Royal Children's Hospital, Melbourne

Starship Hospital, Auckland

All Listed Sponsors
collaborator

Telethon Kids Institute

OTHER

lead

The University of Queensland

OTHER

NCT01270074 - Prevention of Bronchiectasis in Infants With Cystic Fibrosis | Biotech Hunter | Biotech Hunter